Botanix yesterday reported to the Australian Securities Exchange its first safety study on humans, the West Australian reported.
The second phase of clinical trials of the treatment will start within months according to Botanix executive director Matthew Callahan.
“Collectively, our findings suggest that, due to the combined lipostatic, antiproliferative and anti-inflammatory effects, CBD has potential as a promising therapeutic agent for the treatment of acne vulgaris,” the study found.
The most common adverse effect was skin dryness according to the first trials.